Q1 2026 · 13F-HR
Casdin Capital, LLCholdings as filed
Filed 2026-05-15 · accession 0000919574-26-003451
$1.32B
Reported value
40
Positions
2026-03-31
Period end
The Brief · Casdin Capital, LLC · Q1 2026
AI · grounded in 13F
Casdin Capital, LLC closed its position in Avidity Biosciences Inc RNAGBP, reducing exposure by $72.13M. The fund established new positions in Agomab Therapeutics NV AGMB for $16.26M and Qiagen NV QGEN for $14.41M. Additionally, the fund increased its holdings in 10x Genomics Inc TXG by 62.5% and Relay Therapeutics Inc RLAY by 10.88%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $250.6M | 19.0% | 2,577,333 | Common | SOLE |
| 81663L200 | WGS | GENEDX HOLDINGS CORP | $193.1M | 14.6% | 3,007,164 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $143.5M | 10.9% | 14,418,574 | Common | SOLE |
| 09062W204 | BLFS | BIOLIFE SOLUTIONS INC | $113.7M | 8.61% | 5,957,165 | Common | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $81.6M | 6.18% | 88,783,856 | Common | SOLE |
| 452327109 | ILMN | ILLUMINA INC | $65.3M | 4.95% | 530,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $56.6M | 4.29% | 1,175,000 | Common | SOLE |
| 88025U109 | TXG | 10X GENOMICS INC | $48.3M | 3.66% | 2,275,000 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $35.3M | 2.68% | 1,840,000 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $32.2M | 2.44% | 1,350,000 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $29.1M | 2.20% | 315,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $28.6M | 2.17% | 1,420,361 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $24.8M | 1.88% | 75,000 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $22.7M | 1.72% | 758,857 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $17.2M | 1.30% | 350,000 | Common | SOLE |
| 00860C102 | AGMB | AGOMAB THERAPEUTICS NV | $16.3M | 1.23% | 1,550,000 | Common | SOLE |
| 433000106 | HIMS | HIMS & HERS HEALTH INC | $14.5M | 1.10% | 700,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $14.5M | 1.10% | 3,250,000 | Common | SOLE |
| N72482156 | QGEN | QIAGEN NV | $14.4M | 1.09% | 360,000 | Common | SOLE |
| 88023B103 | TEM | TEMPUS AI INC | $13.3M | 1.01% | 294,127 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $13.3M | 1.01% | 553,268 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $11.9M | 0.90% | 230,000 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $11.0M | 0.83% | 3,167,175 | Common | SOLE |
| 71535D106 | PSNL | PERSONALIS INC | $10.2M | 0.77% | 1,600,000 | Common | SOLE |
| 74834L100 | DGX | QUEST DIAGNOSTICS INC | $9.8M | 0.74% | 50,000 | Common | SOLE |
| 92337F107 | VCYT | VERACYTE INC | $8.9M | 0.67% | 276,308 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $8.4M | 0.64% | 450,000 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $4.6M | 0.34% | 355,000 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $4.2M | 0.31% | 65,000 | Common | SOLE |
| 60770K107 | MRNA | MODERNA INC | $3.8M | 0.29% | 75,000 | Common | SOLE |
| 00704R109 | ANL | ADLAI NORTYE LTD | $3.7M | 0.28% | 538,461 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $3.1M | 0.23% | 186,014 | Common | SOLE |
| 00091E109 | ABSI | ABSCI CORPORATION | $2.9M | 0.22% | 973,260 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $2.8M | 0.21% | 1,228,190 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $2.5M | 0.19% | 282,312 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $1.9M | 0.15% | 148,333 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES CALIF IN | $955,372 | 0.07% | 723,767 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $507,542 | 0.04% | 165,323 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $250,627 | 0.02% | 361,969 | Common | SOLE |
| 37611X209 | DNA | GINKGO BIOWORKS HOLDINGS INC | $223,702 | 0.02% | 36,493 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.